Education
About Us
Working with TipRanks
Follow Us
Cidara Therapeutics Inc. (CDTX)
:CDTX
Total Valuation
Cidara Therapeutics has a market cap or net worth of $205.27M. The enterprise value is $68.88M.
Market Cap$205.27M
Enterprise Value$68.88M
Share Statistics
Cidara Therapeutics has 10.95M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding10.95M
Owned by Insiders18.54%
Owned by Instutions25.96%
Financial Efficiency
Cidara Therapeutics’s return on equity (ROE) is -1.04 and return on invested capital (ROIC) is -105.52%.
Return on Equity (ROE)-103.99%
Return on Assets (ROA)-79.06%
Return on Invested Capital (ROIC)-105.52%
Return on Capital Employed (ROCE)-106.57%
Revenue Per Employee$230,657.895
Profits Per Employee-$4,409,947.368
Employee Count38
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Cidara Therapeutics is -1.01. Cidara Therapeutics’s PEG ratio is >-0.01.
PE Ratio-1.01
PS Ratio133.87
PB Ratio1.05
Price to Fair Value1.05
Price to FCF-0.97
Price to Operating Cash Flow-0.97
PEG Ratio>-0.01
Income Statement
In the last 12 months, Cidara Therapeutics had revenue of $8.77M and earned -$167.58M in profits. Earnings per share was -$32.37.
Revenue$8.77M
Gross Profit$7.14M
Operating Income-$93.37M
Pretax Income-$172.44M
Net Income-$167.58M
EBITDA-92.79M
Earnings Per Share (EPS)-32.37
Cash Flow
In the last 12 months, operating cash flow was -$176.53M and capital expenditures -$129.00K, giving a free cash flow of -$176.66M billion.
Operating Cash Flow-$176.53M
Free Cash Flow-$176.66M
Free Cash Flow per Share-$16.13
Dividends & Yields
Cidara Therapeutics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-103.51%
Earnings Yield-99.50%
Stock Price Statistics
Beta1.24
52-Week Price Change13.64%
50-Day Moving Average21.42
200-Day Moving Average16.70
Relative Strength Index (RSI)44.39
Average Volume (3m)179.00K
Important Dates
Cidara Therapeutics upcoming earnings date is May 8, 2025, TBA.
Last Earnings DateMar 6, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend Date―
Financial Position
Cidara Therapeutics as a current ratio of 4.25, with Debt / Equity ratio of 0.02
Current Ratio4.25
Quick Ratio4.25
Debt to Market Cap0.02
Net Debt to EBITDA1.06
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Cidara Therapeutics has paid -$4.86M in taxes.
Income Tax-$4.86M
Effective Tax Rate0.00%
Enterprise Valuation
Cidara Therapeutics EV to EBITDA ratio is 0.09, with an EV/FCF ratio of 0.09.
EV to Sales-12.21
EV to EBITDA0.09
EV to Free Cash Flow0.09
EV to Operating Cash Flow0.09
Balance Sheet
Cidara Therapeutics has $189.82M in cash and marketable securities with $3.58M in debt, giving a net cash position of -$186.25M billion.
Cash & Marketable Securities$189.82M
Total Debt$3.58M
Net Cash-$186.25M
Net Cash Per Share-$17.00
Tangible Book Value Per Share$25.72
Margins
Gross margin is -6557.49%, with operating margin of -13811.92%, and net profit margin of -13319.76%.
Gross Margin-6557.49%
Operating Margin-13811.92%
Pretax Margin-13356.16%
Net Profit Margin-13319.76%
EBITDA Margin-13811.92%
EBIT Margin-13811.92%
Analyst Forecast
The average price target for Cidara Therapeutics is $37.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$37.50
Price Target Upside100.11%
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast-86.28%
EPS Growth Forecast-476.70%